Activated BRAF can promote oncogenesis by activating downstream MEK‐ERK signaling, and the AGK‐BRAF fusion has been identified previously in lung and other cancer types.30, 31, 32 This is a compelling finding in that if this AGK‐BRAF fusion had been detected during clinical care, the result may have informed clinical management with consideration of BRAF targeted therapy. The gene discussed is MAP2K7; the disease is cancer.